CH635746A5 - Medicament agissant sur le systeme nerveux central, a base d'aryl-2 allophanate d'ethyle. - Google Patents
Medicament agissant sur le systeme nerveux central, a base d'aryl-2 allophanate d'ethyle. Download PDFInfo
- Publication number
- CH635746A5 CH635746A5 CH1218578A CH1218578A CH635746A5 CH 635746 A5 CH635746 A5 CH 635746A5 CH 1218578 A CH1218578 A CH 1218578A CH 1218578 A CH1218578 A CH 1218578A CH 635746 A5 CH635746 A5 CH 635746A5
- Authority
- CH
- Switzerland
- Prior art keywords
- scs
- allophanate
- ethyl
- phenyl
- general formula
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title claims description 6
- PIHPSKJRLDSJPX-UHFFFAOYSA-N ethyl n-carbamoylcarbamate Chemical compound CCOC(=O)NC(N)=O PIHPSKJRLDSJPX-UHFFFAOYSA-N 0.000 title 1
- VCGUVRCFKLUCRS-UHFFFAOYSA-N ethyl n-carbamoyl-n-phenylcarbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC=C1 VCGUVRCFKLUCRS-UHFFFAOYSA-N 0.000 claims description 29
- BTPKCEPCEQYPJZ-UHFFFAOYSA-N ethyl n-(2-bromophenyl)-n-carbamoylcarbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC=C1Br BTPKCEPCEQYPJZ-UHFFFAOYSA-N 0.000 claims description 22
- DIPOJLBMCDRHCA-UHFFFAOYSA-N ethyl n-carbamoyl-n-(2-chlorophenyl)carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC=C1Cl DIPOJLBMCDRHCA-UHFFFAOYSA-N 0.000 claims description 18
- FTERQIIEPDJLQN-UHFFFAOYSA-N ethyl n-carbamoyl-n-[2-(trifluoromethyl)phenyl]carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC=C1C(F)(F)F FTERQIIEPDJLQN-UHFFFAOYSA-N 0.000 claims description 17
- IMULWFGAZXIYLS-UHFFFAOYSA-N ethyl n-carbamoyl-n-(2,3-dimethylphenyl)carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC(C)=C1C IMULWFGAZXIYLS-UHFFFAOYSA-N 0.000 claims description 16
- UFLRKWJTMZTORL-UHFFFAOYSA-N ethyl n-carbamoyl-n-(4-methylphenyl)carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=C(C)C=C1 UFLRKWJTMZTORL-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- JBXRVPQIENCZJO-UHFFFAOYSA-N ethyl n-carbamoyl-n-(4-chlorophenyl)carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=C(Cl)C=C1 JBXRVPQIENCZJO-UHFFFAOYSA-N 0.000 claims description 15
- OPCVVGLOBPMWQG-UHFFFAOYSA-N ethyl n-(4-bromophenyl)-n-carbamoylcarbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=C(Br)C=C1 OPCVVGLOBPMWQG-UHFFFAOYSA-N 0.000 claims description 13
- NEGMEIHYNPTRGY-UHFFFAOYSA-N ethyl n-carbamoyl-n-(3-chlorophenyl)carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC(Cl)=C1 NEGMEIHYNPTRGY-UHFFFAOYSA-N 0.000 claims description 13
- NYCSDKZTPBDZGE-UHFFFAOYSA-N ethyl n-(3-bromophenyl)-n-carbamoylcarbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC(Br)=C1 NYCSDKZTPBDZGE-UHFFFAOYSA-N 0.000 claims description 12
- XIKPYGNPUIVKGX-UHFFFAOYSA-N ethyl n-carbamoyl-n-[3-(trifluoromethyl)phenyl]carbamate Chemical compound CCOC(=O)N(C(N)=O)C1=CC=CC(C(F)(F)F)=C1 XIKPYGNPUIVKGX-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- -1 ethyl (2,3-dimethyl-phenyl) Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 description 34
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 25
- 229960004815 meprobamate Drugs 0.000 description 25
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 22
- 229960003529 diazepam Drugs 0.000 description 22
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 21
- 229960002060 secobarbital Drugs 0.000 description 21
- 230000000949 anxiolytic effect Effects 0.000 description 14
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 12
- 206010010904 Convulsion Diseases 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000036461 convulsion Effects 0.000 description 9
- 230000011514 reflex Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000002249 anxiolytic agent Substances 0.000 description 8
- 230000000147 hypnotic effect Effects 0.000 description 8
- 239000003158 myorelaxant agent Substances 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 230000001079 digestive effect Effects 0.000 description 7
- 229960005152 pentetrazol Drugs 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 6
- 241001279009 Strychnos toxifera Species 0.000 description 6
- 230000001773 anti-convulsant effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 229960005453 strychnine Drugs 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003179 convulsant agent Substances 0.000 description 3
- 230000002920 convulsive effect Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012345 traction test Methods 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000007945 N-acyl ureas Chemical class 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000034622 regulation of systemic arterial blood pressure by atrial baroreceptor feedback Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7735907A FR2409752A1 (fr) | 1977-11-29 | 1977-11-29 | Medicament agissant notamment sur le systeme nerveux central a base d'aryl-2 allophanates d'ethyle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH635746A5 true CH635746A5 (fr) | 1983-04-29 |
Family
ID=9198212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1218578A CH635746A5 (fr) | 1977-11-29 | 1978-11-28 | Medicament agissant sur le systeme nerveux central, a base d'aryl-2 allophanate d'ethyle. |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS606331B2 (it) |
| BE (1) | BE872163A (it) |
| CH (1) | CH635746A5 (it) |
| DE (1) | DE2851495C2 (it) |
| FR (1) | FR2409752A1 (it) |
| GB (1) | GB2010812B (it) |
| IE (1) | IE47594B1 (it) |
| IT (1) | IT1107673B (it) |
| LU (1) | LU80573A1 (it) |
| NL (1) | NL7811642A (it) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2572726B1 (fr) * | 1984-11-08 | 1986-12-19 | Francaise Sucrerie | Phenyl-2 allophanate d'isopropyle, son procede d'obtention et son application dans le domaine pharmaceutique |
| WO2026057953A1 (fr) | 2024-09-13 | 2026-03-19 | Lesaffre Et Compagnie | Synthese d'ethanol par hydrogenation de dioxyde de carbone |
-
1977
- 1977-11-29 FR FR7735907A patent/FR2409752A1/fr active Granted
-
1978
- 1978-11-21 BE BE191846A patent/BE872163A/xx not_active IP Right Cessation
- 1978-11-23 GB GB7845728A patent/GB2010812B/en not_active Expired
- 1978-11-24 LU LU80573A patent/LU80573A1/xx unknown
- 1978-11-27 NL NL7811642A patent/NL7811642A/xx not_active Application Discontinuation
- 1978-11-28 DE DE2851495A patent/DE2851495C2/de not_active Expired
- 1978-11-28 IT IT52098/78A patent/IT1107673B/it active
- 1978-11-28 JP JP53147065A patent/JPS606331B2/ja not_active Expired
- 1978-11-28 IE IE2353/78A patent/IE47594B1/en unknown
- 1978-11-28 CH CH1218578A patent/CH635746A5/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL7811642A (nl) | 1979-05-31 |
| JPS5492939A (en) | 1979-07-23 |
| DE2851495A1 (de) | 1979-05-31 |
| FR2409752A1 (fr) | 1979-06-22 |
| IE47594B1 (en) | 1984-05-02 |
| IT1107673B (it) | 1985-11-25 |
| JPS606331B2 (ja) | 1985-02-18 |
| BE872163A (fr) | 1979-05-21 |
| IT7852098A0 (it) | 1978-11-28 |
| FR2409752B1 (it) | 1982-11-12 |
| LU80573A1 (fr) | 1979-06-15 |
| GB2010812A (en) | 1979-07-04 |
| DE2851495C2 (de) | 1982-06-24 |
| GB2010812B (en) | 1982-05-19 |
| IE782353L (en) | 1979-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0068999B1 (fr) | Dérivés d'aryl-1 aminométhyl-2 cyclopropanes carboxamides (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement des troubles du système nerveux central | |
| FR2492258A1 (fr) | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole | |
| WO2012042042A1 (en) | Selective lsd1 and dual lsd1/mao-b inhibitors for modulating diseases associated with alterations in protein conformation | |
| JPS628424B2 (it) | ||
| CH647757A5 (fr) | Derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee. | |
| FR2559061A1 (fr) | Compositions analgesiques et anti-inflammatoires contenant de la diphenhydramine | |
| US20200207691A1 (en) | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | |
| MC1982A1 (fr) | Procede de preparation de derives de la didesoxycitidine | |
| CA2730302C (fr) | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson | |
| Kimura et al. | N-(6-phenylpyridazin-3-yl) benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors | |
| MC2029A1 (fr) | (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments | |
| JP2018021023A (ja) | （ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型 | |
| JP2014514259A (ja) | 疼痛および他の障害の処置のための化合物および方法 | |
| CA2372492A1 (en) | Cyclic amidines useful as nmda nr2b antagonists | |
| CH635746A5 (fr) | Medicament agissant sur le systeme nerveux central, a base d'aryl-2 allophanate d'ethyle. | |
| AU2017213007B2 (en) | Application of substituted cinnamamide derivatives in preparation of anti-anxiety medications | |
| JPS5829708A (ja) | 痙「れん」 | |
| JPH03866B2 (it) | ||
| FR2480285A1 (fr) | 2-(3-(4-(3-chloro-4-fluorophenyl) -1- piperazinyl) propyl)-1,2,4-triazolo(4,3-a)pyridin-3 (2h)-one, procede de preparation et compositions pharmaceutiques | |
| Khan et al. | Exploration for the opioidergic, GABAergic and histaminergic potentials of synthesized Schiff’s base derivatives: An in-vivo approach | |
| US20040209959A1 (en) | Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation | |
| Conti et al. | Selective agonists and antagonists for kainate receptors | |
| LU83713A1 (fr) | Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant | |
| SU940645A3 (ru) | Способ получени производных 1,1 @ -бифенил-2-илалкиламина | |
| NL8204462A (nl) | Benzylideenderivaten, de bereiding hiervan en de therapeutische toepassing. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |